

haynes|boone
Are you changing?
www.haynesboone.com

HAYNES AND BOONE, LLP
Fax Transmittal

DATE: January 14, 2004

Total Pages Including Cover: 9

TO: Commissioner for Patents

Fax #: 703-872-9306

Client/Matter #: 32187.20

FROM: Gloria L. Norberg, Ph.D.

Haynes and Boone, LLP
600 Congress Avenue, Suite 1300
Austin, Texas 78701-3236

I.D. #: 80697

Direct Phone #: 512-867-8528

Direct Fax #: 512-867-8632

Main Phone #: (512) 867-8400

E-Mail: gloria.norberg@haynesboone.com

Main Fax #: (512) 867-8470

Should you have any problems with this transmittal, please call: 512-867-8522

MESSAGE:

Confidentiality Note: The information contained in this facsimile message is privileged and confidential and is intended only for the use of the addressee. The term "privileged and confidential" includes, without limitation, attorney-client privileged communications, attorney work product, trade secrets, and any other proprietary information. Nothing in this facsimile is intended by the attorney or the client to constitute a waiver of the confidentiality of this message. If the reader of this message is not the intended recipient, or employee/agent of the intended recipient, you are hereby notified that any duplication, or distribution of this communication is unauthorized. If you have received this message in error, please notify us by telephone immediately so that we can arrange for the return of the original documents to us at no cost to you.

PATENT / DOCKET NO.: 32187.20
CUSTOMER NO.: 27683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Dupont, et al.

Serial No. 10/688,043

Filed: October 17, 2003

For: SHARK CARTILAGE EXTRACT:
PROCESS OF MAKING, METHODS OF
USING, AND COMPOSITIONS THEREOF§
§
§
§
§
§
§
§

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

OFFICIAL

RECEIVED
CENTRAL FAX CENTER

JAN 14 2004

TRANSMITTALCommissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Enclosed are the following regarding the above-identified patent application:

1. Information Disclosure Statement;
2. PTO-1449 Form; and
3. Transmittal letter.

No fees are believed due for the filing of the present documents, however, should any fees be deemed necessary, the Commissioner is hereby authorized to charge any fees which may be required to Deposit Account 08-1394.

Respectfully submitted,

*Gloria L. Norberg*Gloria L. Norberg
Agent for Applicant
Registration No.: 36,706Date: *January 14, 2004*
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 512-867-8528
Facsimile: 512-867-8632

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below:	
Fax Number: (703) 872-8308	
<i>Tulie Schwartz</i>	
TYPE OR PRINT NAME	
<i>Tulie Schwartz</i>	
SIGNATURE	
<i>01/14/04</i>	
DATE OF TRANSMISSION	

PATENT / DOCKET NO.: 32187.20
CUSTOMER NO.: 27683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	§	
Dupont, et al.	§	Group Art Unit: Not Yet Assigned
	§	
Serial No. 10/688,043	§	
	§	Examiner: Not Yet Assigned
Filed: October 17, 2003	§	
	§	
For: SHARK CARTILAGE EXTRACT:	§	
PROCESS OF MAKING, METHODS OF		
USING, AND COMPOSITIONS THEREOF		

INFORMATION DISCLOSURE STATEMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists. The cited patents are listed in numerical order and are not in any order based on their pertinence.

This Information Disclosure Statement is being filed within three months of the United States filing date. No certification or fee is required (37 CFR §1.97(b)(1)).

The present application claims priority to USSN 10/068,950, filed February 7, 2002 now issued as U.S. 6,635,285, October 21, 2003. Pursuant to 37 CFR §1.98(d), copies of the references provided in the parent application, U.S. Serial No. 10/068,950, are not provided. Pursuant to the Official Gazette Notice of August 5, 2003, copies of U.S. Patents are not provided since the present application was filed after June 30, 2003.

It is requested that the Examiner fully consider the cited references and that they be cited on the front of any patent issuing from this application.

No fees are believed due for the filing of the present Information Disclosure Statement, however, should any fees be deemed necessary, the Commissioner is hereby authorized to charge any fees which may be required to Deposit Account 08-1394.

A-158336_1 DOC

PATENT / DOCKET NO.: 32187.20
CUSTOMER NO.: 27683

It is respectfully requested that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted,

Gloria L. Norberg

Gloria L. Norberg
Agent for Applicant
Registration No.: 36,706

Date: *January 14, 2004*
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 512-867-8528
Facsimile: 512-867-8632

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
Fax Number: (703) 872-9308	
<i>Julie Schwartz</i>	
TYPE OR PRINT NAME	
<i>Julie Schwartz</i>	
SIGNATURE	
<i>01/14/04</i>	
DATE OF TRANSMISSION	

In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		10/688,043	
		Filing Date		October 17, 2003	
		Applicant(s)		Dupont, et al.	
		Art Unit		Not Yet Assigned	
		Examiner Name		Not Yet Assigned	
SHEET 1 OF 5		Attorney Docket Number		32187.20	

U. S. PATENT DOCUMENTS				
Examiner's Initials	Cite No.	Document Number	Publication Date (MM-DD-YYYY)	Name of Patentee or Applicant of Cited Document
		3,478,146	11-11-1969	Balassa
		Re. 28,093	07-30-1974	Balassa
		3,966,908	06-29-1976	Balassa
		4,042,457	08-16-1977	Kuettner, et al.
		4,212,857	07-15-1980	Balassa, et al.
		4,243,582	01-06-1981	Spilburg, et al.
		4,350,682	09-21-1982	Balassa
		4,356,261	10-26-1982	Kuettner
		4,444,752	04-24-1984	Prudden
		4,456,589	06-26-1984	Holman, et al.
		4,469,676	09-04-1984	Hecmati
		4,473,551	09-25-1984	Schinitsky
		4,656,137	04-07-1987	Balassa
		4,746,729	05-24-1988	Kuettner, et al.
		4,749,522	06-07-1988	Kamarei
		4,822,607	04-18-1989	Balassa, et al.
		5,075,112	12-24-1991	Lane
		5,096,892	03-17-1992	Folkman, et al.
		5,135,919	08-04-1992	Folkman, et al.
		5,583,153	10-10-1996	Brahn
		5,618,925	04-08-1997	Dupont, et al.
		5,843,920	12-01-1998	Weisz
		5,985,839	11-16-1999	Dupont, et al.
		6,025,334	02-15-2000	Dupont, et al.
		6,028,118	02-22-2000	Dupont, et al.
		6,168,807	01-02-2001	Dupont, et al.
		6,380,366	04-30-2002	Dupont, et al.
		6,635,285	10-21-2003	Dupont, et al.

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date (MM-DD-YYYY)	Patentee or Applicant of Cited Document	Translation
		WO 9309766	05-27-1993	Hartung	
		WO 9412510	06-09-1994	Lane	
		WO 9503036	02-02-1995	Arsenault, et al.	
		WO 9532722	12-07-1995	Dupont, et al.	
		WO 9623512	08-08-1996	Dupont, et al.	
		WO 9716197	05-09-1997	Dupont, et al.	
		JP 45001444	01-19-1970	Furuhashi	Abstract
		JP 59039828	03-05-1984	Suzuki Fujio, et al.	Abstract
		JP 60178820	09-12-1985	Suzuki Fujio, et al.	Abstract

In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		10/688,043	
		Filing Date		October 17, 2003	
		Applicant(s)		Dupont, et al.	
		Art Unit		Not Yet Assigned	
		Examiner Name		Not Yet Assigned	
SHEET 2 OF 5		Attorney Docket Number		32187.20	

OTHER PRIOR ART		
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS); title of the article; title of the item; date; page(s); volume; issue number(s); pub./sher.; city/country where published
		OIKAWA, T., et al., "A novel angiogenic inhibitor derived from Japanese shark cartilage (I). Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis," <i>Cancer Letters</i> , 51 (1990) 181-186.
		MOSES, M., et al., "Inhibitors of Angiogenesis," <i>Biotech</i> 1991, 9, pp. 630-634.
		FOLKMAN, J., et al., "Angiogenic Factors," <i>Science</i> , Vol. 235, pp. 442-446.
		LUER, C.A., "Inhibitors of Angiogenesis from Shark Cartilage," <i>Fed. Proc.</i> 45(4):949.
		SUZUKI, et al., "Cartilage-derived Antitumor Factor (CATF): A High Molecular Weight Fraction Cartilage Extract Inhibits Solid Tumor Growth," <i>Journal of Bone and Mineral Metabolism</i> , 1984 Vol. 2, No. 3, pp. 53-57.
		LANGER, R., et al., "Isolation of a Cartilage Factor That Inhibits Tumor Neovascularization," <i>Science</i> , Vol. 193, pp. 70-72.
		SORGENTE, N., et al., "The Resistance of Certain Tissues to Invasion," <i>Laboratory Investigation</i> , Vol. 32, No. 2, 1975, pp. 217-222.
		BREM, H., et al., "Inhibition of Tumor Angiogenesis Mediated by Cartilage," <i>The Journal of Experimental Medicine</i> , Vol. 141, 1975, pp. 427-439.
		KUETTNER, K., et al., "Tumor Cell Collagenase and Its Inhibition by a Cartilage-Derived Protease Inhibitor," <i>Science</i> , Vol. 196, pp. 653-654.
		WEINGARTEN, M., et al., "Synthetic Substrates of Vertebrate Collagenase," <i>Biochemistry</i> 24, 6730-6734 (1985).
		SADOVE, A., et al., "Inhibition of Mammary Carcinoma Invasiveness with Cartilage-Derived Inhibitor," <i>Orthopaedic Surgery</i> , pp. 499-501.
		PAULL, B., et al., "Regulation of Tumor Invasion by Cartilage-Derived Anti-Invasion Factor in Vitro," <i>JNCI</i> , Vol. 67, No. 1, pp. 65-73 (1981).
		MORALES, T., et al., "Characterization of the Metalloproteinase Inhibitor Produced by Bovine Articular Chondrocyte Cultures," <i>Biochimic et Biophysica Acta</i> , 760, pp. 221-229 (1983).
		MOSES, M., et al., "Identification of an Inhibitor of Neovascularization from Cartilage," <i>Science</i> , Vol. 248, pp. 1408-1410.
		MOSES, M., et al., "A Metalloproteinase Inhibitor as an Inhibitor of Neovascularization," <i>Journal of Cellular Biochemistry</i> , Vol. 47, pp. 230-235 (1991).
		MOSES, M., "A Cartilage-Derived Inhibitor of Neovascularization and Metalloproteinases," <i>Clinical and Experimental Rheumatology</i> 11 (Supp. 8), pp. S67-S69 (1993).
		MOSES, M., et al., "Metalloproteinase Inhibition as a Mechanism for the Inhibition of Angiogenesis," <i>Angiogenesis: Key Principles-Science-Technology-Medicine</i> , pp. 146-151, (1992).
		McGUIRE, T., et al., "Antiproliferative Activity of Shark Cartilage With and Without Tumor, Necrosis Factor- α in Human Umbilica Vein Endothelium," <i>Pharmacotherapy</i> , 1996, 16(2), p. 237.
		LEE, A., et al., "Shark Cartilage Contains Inhibitors of Tumor Angiogenesis," <i>Science</i> , Vol. 221, pp. 1186-1187.
		MEDINA, "Mammary Tumorigenesis in Chemical Carcinogen-Treated Mice. VI. Tumor-Producing Capabilities of Mammary Dysplasias in BALB/cCrgl Mice," <i>J. Natl. Cancer Inst.</i> , Vol. 57, No. 5, pp. 1185-1189.

In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known							
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number		10/688,043							
		Filing Date		October 17, 2003							
		Applicant(s)		Dupont, et al.							
		Art Unit		Not Yet Assigned							
		Examiner Name		Not Yet Assigned							
SHEET		3		OF		5		Attorney Docket Number		32187.20	

	DAVIS, P., et al., "Inhibition of Angiogenesis by Oral Ingestion of Powdered Shark Cartilage in a Rat Model," Microvascular Research, Vol. 54, pp. 178-182 (1997).
	MATHEWS, J., "Media Feeds Frenzy Over Shark Cartilage as Cancer Treatment," Journal of the National Cancer Institute, Vol. 85, No. 15, p. 1190 (1993).
	SCOTT, et al., "Selective Demineralization of Hard Tissues in Organic Solvents: Retention or Extraction of Proteoglycan?", J. Microsc., 134(3), pp. 291-291.
	PAVIA, et al., "Introduction to Organic Laboratory Techniques a Contemporary Approach," 2 nd Ed., Saunders College Publishing, Philadelphia, pp. 500-501.
	BURDICK, et al., "High Purity Solvent Guide," 2nd Ed., Burdick & Johnson Laboratories, Inc., pp. 128-137.
	SHEU, et al., "Effect of U-995, a Potent Shark Cartilage-Derived Angiogenesis Inhibitor, an, Anti-Angiogenesis and Anti-Tumor Activities," Abtucabcer Research, 18L, 4435-4442 (1998).
	ARNETT, F., et al., Arthritis & Rheumatism, 31(3):315-324 (1988).
	CHABOT-FLETCHER, M., et al., "Interleukin-8 Production is Regulated by Protein Kinase C in Human Keratinocytes," The Journal of Investigative Dermatology, 103(4): 509-515 (1994).
	ELIAS, P.M., "Epidermal Lipids, Barrier Function, and Desquamation," J. Invest. Dermatol., 80:044s-049s (1993).
	GROVE, G.L., "Age-Related Differences in Healing of Superficial Skin Wounds in Humans", The effects of aging in oral mucosa and skin, Ed. Squier & Hill CRC Press, pp. 121-127.
	MATSUI, M.S., et al., "Protein Kinase C in Normal Human Epidermal Keratinocytes During Proliferation and Calcium-Induced Differentiation," J. Invest. Dermatol. 99:565-571 (1992).
	MEDINA, D., et al., "Response of Hyperplastic Aveolar Nodule Outgrowth-Line D1 to Mammary Tumor Virus, Nodule-Inducing Virus, and Prolonged . . .", J. Natl. Cancer Inst. 42:303-310, (1969).
	NICKOLOFF, B.J., et al., "Aberrant Production of Interleukin-8 and Trombospondin-1 Psoriatic Keratinocytes Mediates Angiogenesis," Am. J. Pathology 144(4):820-828 (1994).
	ORESAJO, C., et al., "Eye Area Problems Puffiness, Bags, Dark Circles and Crowsfeet," Cosmetics and Toiletries 102:29-34 (1987).
	PINNAGODA, "Guidelines for transepidermal water loss (TEWL) measurement," Contact Dermatitis 22:164-178 (1990).
	RITCHIE, et al., "Clinical Studies with an Articular Index for the Assessment of Joint Tenderness in Patients with Rheumatoid Arthritis," Quarterly Journal of Medicine, New Series XXXVII, No 147, pp. 393-407 (1968).
	BLOOD, C.H., et al., "Tumor interactions with the vasculature: angiogenesis and tumor metastasis," Biochimica et Biophysica Acta, 1032:89-118 (1990).
	BREM, S., "Angiogenesis and Cancer Control: From Concept to Therapeutic Trial," JMCC, 6(5):436-458 (1999).
	DAVIS-SMYTH, T., et al., "The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade" The EMBO Journal 15:18, 4919-4927 (1996).
	DUPONT, E., et al., "Antiangiogenic Properties of a Novel Shark Cartilage Extract: Potential Role in the Treatment of Psoriasis," Journal of Cutaneous Medicine and Surgery, 2:3, 146-152, (1998).

In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number		10/688,043	
		Filing Date		October 17, 2003	
		Applicant(s)		Dupont, et al.	
		Art Unit		Not Yet Assigned	
		Examiner Name		Not Yet Assigned	
SHEET 4 OF 5		Attorney Docket Number		32187.20	

	DVORAK, H.F., et al., "Vascular Permeability Factor/Vascular Endothelial Growth Factor and the Significance of Microvascular Hyperpermeability in Angiogenesis," pp. 98-132.
	FAN, T., "Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy," <i>Angiogenesis Review</i> , 16, 57-66 (1995).
	GRIFFIOEN, A., et al., "Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation," <i>Pharmacological Reviews</i> , 52:2, 237-268 (2000).
	HANAHAN, D., et al., "Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis," <i>Cell</i> , 86:353-364 (1996).
	JACKSON, J. R., et al., "The codependence of angiogenesis and chronic inflammation," <i>FASEB J.</i> 11, 457-465 (1997).
	KERR, J. S., et al., "Novel Small Molecule α v Integrin Antagonists: Comparative Anti-Cancer Efficacy with Known Angiogenesis Inhibitors," <i>Anticancer Research</i> , 19:959-968 (1999).
	LAUE, T. M., et al., <i>Methods in Enzymology</i> , 182:566-587 (1990).
	PASSANITI, A., et al., "Methods in Laboratory Investigation: A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor," <i>Laboratory Investigation</i> , 67:4, 519-528 (1992).
	PLUDA, J. M., "Tumor-Associated Angiogenesis: Mechanisms, Clinical Implantations, and Therapeutic Strategies," <i>Seminars in Oncology</i> , 24:2, 202-218 (1997).
	RAJU, K. S., et al., "Characterization of a chemoattractant for endothelium induced by angiogenesis effectors," <i>Cancer Res.</i> , 44(4):1579-84 (1984).
	RAK, J., et al., "Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls," <i>Cancer and Metastasis Reviews</i> 15:231-236 (1996).
	SAUDER, D N., et al., "Angiogenesis in Dermatology," <i>Curr Prob Dermatol</i> , 1-10 (2001).
	SIEMEISTER, G., et al., "Two Independent Mechanisms Essential for Tumor Angiogenesis: Inhibition of Human Melanoma Xenograft Growth by Interfering with either the Vascular Endothelial Growth Factor Receptor Pathway or the Tie-2 Pathway," <i>Cancer Research</i> 59:3185-3191 (1999).
	TAKANO, S., et al., "Concentration of Vascular Endothelial Growth Factor in the Serum and Tumor Tissue of Brain Tumor Patients," <i>Cancer Research</i> 56, 2185-2190 (1996).
	WEBER, G., "Biochemical Strategy of Cancer Cells and the Design of Chemotherapy: G.H.A. Clowes Memorial Lecture," <i>Cancer Research</i> , 43:3466-3492 (1983).
	AUERBACH, W., et al., <i>Pharmac. Ther.</i> 63:265-311 (1994)
	BISCHOFF, J., <i>Trend Cell Biol.</i> , 5:69-74 (1995).
	BROOKS, P.C., <i>Cancer Metastasis Rev.</i> , 15:187-194 (1996).
	BROOKS, P.C., <i>Eur. J. Cancer</i> , 32A:2423-9 (1996)
	BUSSOLINO, F., et al., <i>Eur. J. Cancer</i> , 32A:2401-12 (1996).
	FERRARA, N., <i>Nature</i> , 376-467 (1995)
	FERRARA, N., et al., <i>Endocrine Rev.</i> , 18:4-25 (1997)
	FORM, D., et al., <i>J. Cell Physiol.</i> , 152:196-205 (1992)
	HAMADA, J., et al., <i>Br. J. Cancer</i> , 66:349-354 (1992)
	HANSON, et al., <i>J. Bone & Min. Res.</i> , 7:1251-1258 (1992)
	INGBER, <i>Sem. Cancer Biol.</i> , 3:57-63 (1992)
	JAFFE, et al., <i>J. of Clin. Invest.</i> , 52 :2745-2756 (1973)
	KLGSBRUN, M., et al., <i>Annu. Rev. Physiol.</i> , 53:217-32 (1991)
	KLEIN, S., et al., <i>Mol. Biol. Cell.</i> , 4:973-82 (1993)

In place of PTO-1449 Form		U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	10/688,043
				Filing Date	October 17, 2003
				Applicant(s)	Dupont, et al.
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
SHEET	5	OF	5	Attorney Docket Number	32187.20

	KLEIN, S., et al., J. Biol. Chem., 271:22583-90 (1996)
	KNIGHT, et al., FEBS Let., 296, 263-266 (1992)
	KNIGHTON, D.R., et al., Science, 221:1283-85 (1983)
	KOCH, A.E., et al., Nature, 376:517-19 (1995)
	LAEMMLI, U.K., Nature, 227:680 (1970)
	MAZURE, N.M., et al., Cancer Res., 56:3438-40 (1996)
	MIGNATTI, P., et al., J. Cell. Biol., 113:1193-201 (1994)
	MOSES, M.A., et al., Int. Rev. Cytol., 161:1-48 (1995)
	PEPPER, M.S., et al., J. Cell Physiol., 152:196-205 (1992)
	PEPPER, M.S., et al., Biochem. Biophys. Res. Commun., 189:824-31 (1992)
	POLVERINI, P.J., Eur. J. Cancer, 32A:2430-7 (1996)
	PROOST, P., et al., Int. J. Clin. Lab. Res., 26:211-23 (1996)
	RAK, J., et al., Eur. J. Cancer, 32A:2438-50 (1996)
	RAK, J., et al., J. Cell. Physiol., 159:245-55 (1994).
	ROSEN, et al., Medical Hypotheses, 6:441-446 (1980).
	SANDER, P., et al., Kidney Int., 51:448-53 (1997).
	SCHWARTZ, SM, et al., J Cardiovasc. Pharmacol., 21 SUPPL. 1:S31-S49 (1993).
	SCHWEIGERER, L., et al., Nature, 325:258-9 (1987)
	WELGUS, et al., J. Biol. Chem., 256:9511-9516 (1979)
	WILKIN, J.K., Arch. Dermatol., Vol. 130, 359-362 (1994)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.